Forian Inc.的动态

November is Pancreatic Cancer Awareness Month. To honor the survivors and?bring?further?awareness to this deadly disease, we at?ClearNote?Health want to?share our efforts to help save lives from pancreatic cancer.? ? ClearNote?Health is transforming patient care by improving the detection of high-mortality cancers at earlier, more treatable stages. Three fundamental principles guide our approach:? ? ?? Prioritizing Patients:?Our mission is to help people lead longer, healthier lives.?We are dedicated to delivering actionable test results that help guide more successful cancer interventions. ?? Redefining the Possible:?We push the boundaries of testing technology,?applying our proprietary AI-powered epigenomic test platform to identify specific DNA-based?changes? in the?blood?that may indicate cancer development at it earliest stage.? ? ?? Collaborating for Success:?We partner with healthcare providers worldwide to offer our tests to their patients and collaborate with scientists and?technologists at top academic and research institutions?to guide our product development.? ? Explore our story and cutting-edge approach to early high-mortality cancer?detection at: https://lnkd.in/eVE68cER #PancreaticCancerAwarenessMonth #PanCan #PancreaticCancer #EarlyDetection

A recent study reveals that National Cancer Institute (NCI) Comprehensive Cancer Centers lead to significantly better patient outcomes, with a 23% lower mortality risk and improved symptom control compared to non-NCI centers. But what about the majority of patients who receive care in community oncology practices? This is where VieCure is transforming the landscape. By leveraging our patented AI platform and knowledge base, community oncology centers can deliver personalized, data-driven care that adapts in near real-time to patients' changing needs. In one community network, VieCure has helped to improve NGS testing in identified eligible patients by more than 4x in just 10 months. At VieCure, we’re leveling the playing field. Our technology equips community oncologists with tools that go beyond even those in larger institutions, enabling timely interventions and better patient outcomes—right in the heart of local communities. Cancer care should be exceptional no matter where it’s delivered. We’re proud to support community oncology practices in bringing the highest standard of care to patients everywhere. #VieCure https://lnkd.in/gzKWdRjt

Every 14 seconds, somewhere in the world, a woman is diagnosed with breast cancer… Making it the second most common cancer in the world, according to the Breast Cancer Research Foundation. Early detection literally saves lives. This makes the validity of having an annual Breast Cancer awareness month, held in October, extremely obvious. At LOGEX, we also see Breast Cancer Awareness Month as an important time to reflect on the challenges and advancements in the treatment of patients with breast cancer. Our focus is on leveraging real-world data and analytics. Through collaborations with healthcare providers, researchers, life science companies and patient organisations, we aim to increase the understanding of how care is being provided internationally and how optimisation is possible in order to achieve more positive outcomes at a faster pace for patients. Thu ultimate goal is to reduce the impact of breast cancer on patients and their families. Two examples of our work in this field: 1-?Should breast cancer patients suffer from heartburn to not temper with the effectiveness of their cancer treatment, as is suggested by literature? Our real-world data research implies that the answer is ‘no’: Proton pump inhibitors help reduce heartburn and their use does not show a negative effect on the effectiveness of the cancer treatment: https://lnkd.in/eH6mZd5k. 2- The outcomes of the treatment of breast cancer varies quite significantly, even when looking at just European countries. There are important knowledge gaps in our understanding of how these variations can be explained. LOGEX worked with researchers and hospitals across Europe to gather and analyse real-world data on care paths in different countries, leading to some highly relevant insights and best practices https://lnkd.in/eD-MkV4M. Curious to learn more about how we try to turn data into better healthcare? Visit logex.com. Esther Dronkers,Esmée van Geffen,Naomi de Kruif,Nicole Kerklaan,Femke Oldenziel,Jan van der Eijk,Pieter Krop,Shannen van Duijn,Zelda Odé,Lia Lapian #LOGEX #BreastCancerAwareness #BCAM2024 #EarlyDetectionSavesLives #BreastCancerResearch #FightBreastCancer #HopeForACure #StrongerTogether #RealWorldData #DataForGood #HealthcareInnovation #PatientCare #LOGEXCares #SupportTheCause #PinkRibbonMonth

The President's Cancer Panel Panel released its latest report, Enhancing Patient Navigation with Technology to Improve Equity in Cancer Care. We want to acknowledge and thank Jon Handler, MD for his contributions to the report. The report highlights four priorities for the responsible development and use of technology for patient navigation, along with specific recommendations for ways stakeholders across the cancer community can improve the use of technology to extend the reach of navigation services. Read the Panel’s recommendations in the full report:?https://go.nih.gov/Z63X1mU?#Tech4CancerNavigation

Today, October 17th, is the Day Against Cancer. Innovative cancer treatment is one of the key research areas of the UMCG. To enable better cancer research, UMCG started #OncoLifeS; a comprehensive and high-quality #databank and #biobank. By combining extensive cancer related data and biological samples, OncoLifeS supports the development of personalized patient care and enhances both clinical and translational cancer research through its robust infrastructure. So far, OncoLifeS includes more than 10,000 participants. ? A recent article using OncoLifeS data evaluated current clinical testing guidelines regarding epithelial ovarian cancer, focusing on untested patients. The findings reveal suboptimal testing rates, suggesting that clinicians may overlook testing for non-high-grade serous ovarian carcinoma, despite guidelines recommending testing for all patients. These gaps limit care optimization and hinder counseling for potentially affected relatives, emphasizing the critical need to adhere to cancer testing guidelines to improve treatment outcomes. Such research shows the potential of OncoLifeS to evaluate practical application of guidelines and work towards further improvement of cancer care.? ? Read the full article here: https://lnkd.in/eShfyzpF ? Lieke Lanjouw, Marian Mourits, Joost Bart, Lieke Berger, Annemieke van der Hout, Naufil Alam, Truuske De Bock, Janny Nagel, Jourik Gietema ? #DayAgainstCancer #Biobanks #UMCGResearch #UMCG #CBCH #ClinicalGuidelines

HER2 status plays a critical role in guiding breast cancer treatment but can evolve over time, presenting challenges in patient management. At the 2024 San Antonio Breast Cancer Symposium, we presented preliminary findings on the evolving nature of HER2 biomarkers using Real World Data. This AI-powered analysis, conducted in collaboration with Clinithink and Healthix examined over 3 million clinical records from a diverse NYC population. Our results reveal frequent changes in HER2 status—positive, low, and negative—within the same patients, highlighting the complexity of disease progression and its impact on treatment decisions. Additionally, the study underscores disparities in biomarker testing, with HER2 evaluated more often than markers like PIK3CA or AKT1. These real-world insights from Northwell Cancer Institute and other institutions in the New York Metropolitan area emphasize the importance of continuous biomarker assessment and the potential of advanced AI technologies to inform personalized cancer care, improve treatment planning, and ultimately enhance outcomes for breast cancer patients. ?? #SABCS2024 #BreastCancerResearch #HER2Biomarkers #CancerCare #InnovationInMedicine

How lessons from C/Can’s global network of cities can support the EU Mission on Cancer’s objectives City Cancer Challenge ECHoS | Establishing of Cancer Mission Hubs: Networks and Synergies #OncoDaily #Oncology #Cancer #Health #Medicine #HealthCare #CancerSupport

Event helps close the gap in access to lung cancer screening On Saturday, Nov. 9, the ACS National Lung Cancer Roundtable promoted the third annual National Lung Cancer Screening Day in partnership with GO2 for Lung Cancer, Radiology Health Equity Coalition, and American College of Radiology. Early detection saves lives, yet fewer than 1 in 10 eligible individuals are screened for lung cancer. This initiative aims to address a major barrier to access by encouraging screening centers to open their doors on a Saturday. With most centers operating Monday through Friday, patients who can’t take time off work face significant challenges in getting screened. More than 675 organizations and individuals, including 125 Veterans Affairs Screening Centers, joined forces to host and promote National Lung Cancer Screening Day events, with an incredible 40% of participating sites signing up for the first time this year. The initiative generated nearly 15,000 impressions and 600 engagements across ACS NLCRT’s social media channels, and the President’s Cancer Panel further amplified ACS NLCRT’s message, applauding this effort as a meaningful step toward closing the gap in access to lung cancer screening. I’m thrilled to share that the State of Michigan hosted the most sites. There were 48 sites that opened their doors on this Saturday! Thank you to the many partners we had in Michigan and across the country. #NLCRT #LungCancerAwareness #AmericanCancerSocietyMichigan

This week, the?American Association for Cancer Research?published their annual Cancer Disparities Progress Report for 2024 and one thing is made clear throughout: inequities in cancer care span the entire cancer journey—from screening to treatment and survivorship—underscoring the need for systemic change. Some key highlights from the report: 1?? Cancer Screening Inequities: Despite its life-saving potential, only 64% of eligible Asian and American Indian/Alaska Native individuals are up to date with cervical cancer screening, compared to 78% of White individuals, highlighting access barriers in preventive care. 2?? Treatment Inequities: Black and Hispanic women with triple-negative breast cancer (an aggressive type of breast cancer) are 18% and 13% less likely than White women to receive guideline-adherent treatments, leading to worse outcomes and higher mortality. 3?? Survivorship Care Inequities: Medically underserved populations face higher cancer mortality and worse quality of life after treatment, due to limited follow-up care, more side effects, and financial strain. Everyone should have access to quality care, regardless of who they are or where they live. This requires an approach that is culturally and linguistically accessible, reduces financial burdens, and breaks down logistical barriers for all. See the full study for more insights ↓ https://lnkd.in/gXgZ34k #healthequity #oncology #AACR

CCCZ Strategy Workshop Highlights – 08.07.2024 ? Our latest CCCZ Strategy Workshop brought forward critical discussions and strategic initiatives aimed at enhancing the CCCZ's role in the Swiss cancer care landscape. Here are the key takeaways: ? - Patient Pathways: Launch of a pilot pathway at CCCZ for lung cancer patients with dedicated care coordinators to guide the patient’s journey through the cancer center. - Clinical Trials: The CCCZ is focused on the development of state-of-the-art clinical trials program allowing our patients to benefit from novel diagnostic and therapeutic concepts and the latest research results. - Supportive Services: Enhancing collaboration among >15 supportive care services at the CCCZ to offer cancer patient comprehensive physical, psychosocial and emotional care. - National Cancer Plan Switzerland: The CCCZ aims to support this truly important initiative of a Swiss wide strategy and collaboration in prevention, treatment, and aftercare to beat cancer. ? This workshop marks a pivotal step in aligning our strategies and improving our collaborative efforts to enhance cancer medicine and research in Zurich. ? #CancerCare #CCCZ #StrategyWorkshop #HealthcareInnovation #Oncology #ClinicalTrials #PatientCare #MedicalResearch #HealthcareStrategy